CHU de Lille- Hopital Claude Huriez
Lille 59037
5 studies enrolling now · 13 studies all time
What they study most
Acute GVHD, Acute-graft-versus-host Disease, B-cell Lymphoma, BK Virus Infection, Bladder Carcinoma in Situ (CIS), Colitis, Ulcerative, Colonic Diseases, Colorectal Neoplasms, Crohn Disease, Crohn's Disease, Digestive System Diseases, Digestive System Neoplasms
Studies at this site
- A Protocol of Icotrokinra Therapy in Adult and Adolescent Participants With Moderately to Severely Active Ulcerative Colitis — Recruiting now
- A Study of Icotrokinra in Participants With Moderately to Severely Active Crohn's Disease — Recruiting now
- Symbiotic-GI-03: A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Chemotherapy in Adult Participants With Metastatic Colorectal Cancer — Recruiting now
- A Study to Assess the Efficacy and Safety of Efgartigimod PH20 SC in Adults With Systemic Sclerosis — Recruiting now
- A Study of LY4152199 in Participants With Previously Treated B-cell Malignancies (BAF_FRontier-1 ) — Recruiting now
- ENdoluminal LIGHT ActivatED Treatment of Upper Tract Urothelial Cancer (ENLIGHTED) Study — Running, not enrolling
- A Study Comparing Anitocabtagene Autoleucel to Standard of Care Therapy in Participants With Relapsed/ Refractory Multiple Myeloma — Running, not enrolling
- HAELO: A Phase 3 Study to Evaluate NTLA-2002 in Participants With Hereditary Angioedema (HAE) — Running, not enrolling
- A Study Evaluating the Efficacy and Safety of Oral Etrasimod in the Treatment of Adult Participants With Moderately to Severely Active Crohn's Disease — Stopped early
- Study of ONCOFID-P-B (PACLITAXEL-HYALURONIC ACID) — Running, not enrolling
- MagnetisMM-3: Study Of Elranatamab (PF-06863135) Monotherapy in Participants With Multiple Myeloma Who Are Refractory to at Least One PI, One IMiD and One Anti-CD38 mAb — Running, not enrolling
- A Study of Itolizumab in Combination With Corticosteroids for the First-Line Treatment of Acute Graft Versus Host Disease (EQUATOR) — Stopped early
- Study to Evaluate Viralym-M (ALVR105) for the Treatment of Virus-Associated Hemorrhagic Cystitis (HC) — Stopped early